1. 5-Fluorouracil induced extravasation injury.
- Author
-
Reddy SS, Somayaji S, Krishna Murthy M, and Maka VV
- Subjects
- Cisplatin administration & dosage, Docetaxel administration & dosage, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma pathology, Extravasation of Diagnostic and Therapeutic Materials pathology, Female, Fluorouracil administration & dosage, Humans, Middle Aged, Prognosis, Antineoplastic Combined Chemotherapy Protocols adverse effects, Esophageal Neoplasms drug therapy, Esophageal Squamous Cell Carcinoma drug therapy, Extravasation of Diagnostic and Therapeutic Materials etiology
- Abstract
Antineoplastic drugs based on their ability to cause local damage are classified as irritants, vesicants, and non-vesicants. Previous literature has reported higher rate of vesicants induced extravasation (EV) compared to irritants. We report the first case of irritant, 5-fluorouracil causing grade III EV in 55-year-old woman. The patient was diagnosed with esophageal squamous cell carcinoma. Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) chemotherapy regimen was planned and administered through peripheral venous access. Patient experienced grade 3 extravasation in her 3
rd cycle following 5-fluorouracil (5-FU) administration. The suspected drug was withdrawn immediately and discontinued from the 4th cycle of the regimen. The patient completely recovered from the symptoms of pain and erythema in the next cycle and care was taken not to infuse drug in the same site again. Since there is no appropriate antidote available to manage this condition, measures need to be taken to identify the predisposing factors for EV and prevent them., Competing Interests: None- Published
- 2020
- Full Text
- View/download PDF